No products in the cart.
Rabbit Polyclonal Anti-Flt-4 antibody (STJ98712)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC-P, ELISA
Recommended dilution: WB 1:500-2000; IHC-P 1:50-300; ELISA 1:5000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-Flt-4 antibody.
Check alternative names for the antibodyExpand
|EC 126.96.36.199 antibody|Fms-like tyrosine kinase 4 antibody|LMPH1A antibody|PCL antibody|Soluble VEGFR3 variant 1 antibody|Soluble VEGFR3 variant 2 antibody|Soluble VEGFR3 variant 3 antibody|Tyrosine protein kinase receptor FLT4 antibody|Tyrosine-protein kinase receptor FLT4 antibody|Vascular endothelial growth factor receptor 3 antibody|Vascular endothelial growth factor receptor 3 precursor antibody|VEGF R3 antibody|VEGFR 3 antibody|VEGFR-3 antibody|VEGFR3 antibody|VGFR3_HUMAN antibody|Anti-VEGF Receptor 1 antibody [Y103] (ab32152)
SCBT cat No: sc-316|sc-271789|sc-9029|sc-31173|
|Catalogue No.|| |
Human, Mouse, Rat
Anti-Flt-4 antibody detects endogenous Flt-4.
Synthetic peptide from human protein at AA range: 640-700.
WB, IHC-P, ELISA
|Recommended dilution|| |
WB 1:500-2000; IHC-P 1:50-300; ELISA 1:5000-20000
|Molecular weight|| |
Anti-Flt-4 antibody was tube-contained in PBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.
Anti-Flt-4 antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
EC 188.8.131.52 antibody, Fms-like tyrosine kinase 4 antibody, LMPH1A antibody, PCL antibody, Soluble VEGFR3 variant 1 antibody, Soluble VEGFR3 variant 2 antibody, Soluble VEGFR3 variant 3 antibody, Tyrosine protein kinase receptor FLT4 antibody, Tyrosine-protein kinase receptor FLT4 antibody, Vascular endothelial growth factor receptor 3 antibody, Vascular endothelial growth factor receptor 3 precursor antibody, VEGF R3 antibody, VEGFR 3 antibody, VEGFR-3 antibody, VEGFR3 antibody, VGFR3_HUMAN antibody
|Database links|| |
|Protein function|| |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. .
|Protein tissue specificity|| |
Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney. .
|Involvement in disease|| |
Lymphedema, hereditary, 1A (LMPH1A) [MIM:153100]: A chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Hemangioma, capillary infantile (HCI) [MIM:602089]: A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note=Plays an important role in tumor lymphangiogenesis, in cancer cell survival, migration, and formation of metastases.
|Protein sequence and domain|| |
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. ; Contains 7 Ig-like C2-type (immunoglobulin-like) domains. ; Contains 1 protein kinase domain. The first and second Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFC binding.
|Protein post-translational modifications|| |
Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC at Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337. .
|Protein cellular localization|| |
Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Note=Ligand-mediated autophosphorylation leads to rapid internalization.; Isoform 1: Cell membrane; Single-pass type I membrane protein. Note=Ligand-mediated autophosphorylation leads to rapid internalization.; Isoform 2: Cell membrane; Single-pass type I membrane protein.; Isoform 3: Secreted. Cytoplasm.
|Research area|| |
<a href="http://antibodyplus.com/research-areas/">All research areas</a>><a href="http://antibodyplus.com/Membrane-Receptors/">Membrane Receptors</a>><a href="http://antibodyplus.com/product-tag/Flt/">Flt</a><br><a href="http://antibodyplus.com/product-tag/Membrane-Receptors/"> (View all antibody categories related to Membrane Receptors)</a>
AntibodyPlus can customize Anti-Flt-4 antibody according to your requirement, including bulk product size,etc. Please contact <a href="mailto:firstname.lastname@example.org">email@example.com</a>. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: